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Summary The clinical significance of neuron-specific enolase (NSE) as a tumour marker was evaluated in 54
patients with seminoma. Before orchiectomy NSE was elevated in six out of 21 patients with stage I seminoma
and 11 out of 16 patients with metastases. After orchiectomy NSE normalised in all evaluated stage I cases,
but was still elevated in six out of 12 patients with metastatic disease. NSE monitored the effect of
cisplatin-based chemotherapy in patients with metastases. In some patients, increased serum NSE was found
together with raised levels of human choriogonadotropin (HCG) and lactate dehydrogenase (LDH), while in
others only NSE was elevated. No false positive NSE values were observed.
NSE seems to be a clinically worthwhile serum tumour marker for monitoring seminoma patients, with a
sensitivity and specificity of the same order as HCG.
Accurate monitoring of the disease by repeated serum tu-
mour marker determinations is an important element of the
successful management of malignant germ cell tumours.
In non-seminoma the serum levels of choriogonadotropin
(HCG) and/or of alfa-foeto-protein (AFP) are elevated in
about 70% of the patients with tumour manifestations
(Fossa et al., 1989). HCG is the most specific tumour marker
in seminoma, but with a low sensitivity (Fossa & Fossa,
1989). There is a need for other tumour markers which may
be helpful to monitor the clinical course in patients with
seminoma.
Neuron-specific enolase (NSE) is recognised as a valuable
tumour marker in small cell lung cancer (Carney et al., 1982),
melanoma (Wibe et al., 1990) and other neuroendocrine
malignancies (Heitz, 1987). NSE has been demonstrated in
cells from testicular germ cell tumours, in particular in
seminomas (Kuzmits et al., 1987; Niehans et al., 1988). Based
on small series, Kusznitz et al. (1987) and Takashi et al.
(1990) suggested that NSE may represent a valuable tumour
marker in seminoma (Kuzmits et al., 1987, Takashi et al.,
1990).
The aim of the present retrospective pilot study was fur-
thermore to assess the hypothesis that the determination of
serum NSE might be worthwhile in the management of
patients with seminoma.
Patients and methods
Patients
Serum NSE levels were determined at least once during the
clinical course of 54 patients treated for seminoma at the
Departments of Medical Oncology of the Norwegian Radium
Hospital (NRH), Oslo and at the University Hospital, Trond-
heim. Patients were selected on the basis of availability of
frozen sera (- 40°C) collected and stored either before orchi-
ectomy and/or before start of treatment. The patients were
clinically staged according to the Royal Marsden Hospital
Classification System (Peckham et al., 1979). Treatment con-
sisted of radiotherapy in case of stage I or low volume
metastatic disease (stage IIA/B). Cisplatin-based chemother-
apy was given iflarger metastases were found (extended stage
IIB or stage > IIC) (Fossa et al., 1988).
Human choriogonadotropin (HCG) was determined in all
serum samples in which NSE analyses were performed.
Results of serum lactate dehydrogenase (LDH) analysis were
available in only 31 of the serum samples.
The control group consisted of 16 patients with irradiated
seminoma stage I who had no evidence of disease for at least
1 year after their primary treatment.
Tumour marker analysis
The methods for HCG and LDH analysis have been des-
cribed previously (Fossa & Fossa, 1989). The upper limits of
the normal ranges were 10 U 1 for HCG and 450 U 1-' for
LDH.
NSE was measured by an immunoradiometric assay based
on monoclonal antibodies employing monodisperse magne-
tisable particles as the solid phase (Paus & Nustad, 1989).
This method is specific for y-enolase, measures wy- and yy-
enolase equally well, has a sensitivity of 0.4 tg I1- and an
interassay coefficient of variation below 5% in the working
range from 0.4 to 170 lgl-'. The 97.5th percentile value of
the reference population was found at 8 jig I-I (Paus & Nus-
tad, 1989). NSE values exceeding 8 tgl-1 were considered
elevated. All results are given without decimals.
Results
NSE was < 8 yg l'- in all patients from the control group
(Table Ia).
Before orchiectomy, three of the 21 patients with stage I
seminoma had elevated serum NSE, but normal HCG, and
in three additional patients both markers were increased
(Table Ia). In all four evaluable patients with elevated pre-
orchiectomy serum NSE, this marker normalised after orchi-
ectomy (Figure la).
Eleven of 16 patients with metastases had elevated NSE
before orchiectomy, four of them combined with elevated
HCG. Figure lb shows the serum NSE levels before and
after orchiectomy in seven metastatic patients where such
comparison was possible. After orchiectomy the serum NSE
values remained >8 yg 1- in three out of five patients with
elevated pre-orchiectomy NSE values.
In 15 patients who at the time of sampling had macro-
scopic active disease (stage I before orchiectomy: five pa-
tients; metastatic stage: ten patients) NSE could be compared
with simultaneously analysed LDH levels (Table Tb). Seven
patients had elevated NSE, four of them combined with
elevated LDH. LDH was falsely elevated in one of the 16
patients from the control group.
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Table I NSE in relation to HCG and LDH
Elevated serum levels
a Clinical NSE HCG
situation Total only only NSE + HCG
Stage I
before orchiectomy 21 3 3 3
Stage > I
before orchiectomy 16 7 2 4
Stage > I
after orchiectomy 12 4 1 2
Stage I
after treatment 16 0 0 0
(control group)
b Clinical
situation
Patients with tumour 15 3 2 4
Control group 16 0 1 0
U1)
z
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therapy and remained < 8 jLg I` during follow-up (Figure
2b). After treatment he still had a small residual para-aortic
mass (partial response), a frequent finding after chemo-
therapy of advanced seminoma.
Discussion
The need of new tests to monitor the clinical course of
seminoma is well recognised. HCG is elevated in about
30-50% of the patients with manifest seminoma, dependent
on the assay used (Paus et al., 1988). LDH is elevated in
80% of the patients with active tumour (Fossa & Fossa,
1989), but the high rate of false positive values renders this
marker less valuable in the individual patient. Placental
alkaline phosphatase (PLAP) has until now gained limited
value for routine clinical management of seminoma due to its
high frequency of false positive values as a tumour marker,
especially in smokers (Nielsen et al., 1990).
Kuzmits et al.'s report (1987) and Takashi et al.'s (1990)
reports have suggested that serum NSE may be a useful
serum tumour marker in seminoma. These authors, as well as
Niehans et al. (1988) demonstrated NSE producing cells in
histological sections from seminomatous testicular tumours.
We aimed to re-evaluate Kuzmits et al.'s statement that NSE
may 'a new marker in seminoma and its measurement may
be of clinical value in monitoring chemotherapy in patients
with metastatic seminoma'. Before involving in a larger pro-
spective study we retrospectively analysed samples available
from the serum bank. This bank consists of serum residual
after determination of AFP and HCG. The present study
indicated that the sensitivity of NSE in regard to the presence
of tumour manifestations is within the same range as that of
HCG. Of 33 patients with tumour 12 had elevated NSE and
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Figure 1 Serum NSE levels in patients with seminoma before
and after orchiectomy before further treatment. a, Stage I
seminoma (10). b, Metastatic seminoma (7). (The horizontal line
represents the upper limit of the normal range for NSE).
Figure 2a shows the development of serum NSE in a
patient presenting with seminoma stage I who developed
skeletal metastases 8 months after infradiaphragmatic radio-
therapy and responded completely to subsequent chemother-
apy/radiotherapy. The first serum NSE level (10igl1') was
available 2 months after infradiaphragmatic radiotherapy.
Four months later he presented with bone metastases. Serum
NSE was at that time measured on two occasions (22 jig 1-
and 43 jg 1 '). After subsequent chemotherapy and radio-
therapy serum NSE normalised. In this patient, HCG re-
mained normal during the course of the disease, while LDH
was elevated before start of chemotherapy and normalised
subsequently. In another patient with an extragonadal stage
IIIC seminoma with raised pre-treatment values of NSE and
HCG the nrarkers normalised after cisplatin-based chemo-
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Figure 2 Serum NSE levels during treatment of metastatic
seminoma. a, Patient with stage IV disease (relapse after stage I)
treated with chemotherapy followed by radiotherapy. b, Patient
with initial stage IIIC disease treated with chemotherapy. (The
horizontal line represents the upper limit of the normal range for
NSE).
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nine raised HCG. NSE was the only elevated marker in two
out of 14 patients with tumour, in whom both NSE, LDH
and HCG were determined. No patient with falsely elevated
NSE was observed.
Changes of NSE efficiently monitored treatment response:
In stage I seminoma orchiectomy led to normalisation of
NSE in all patients who had elevated values before the
operation. During chemotherapy any raised NSE levels nor-
malised in all patients. NSE might be elevated due to other
malignancies (Carney et al., 1982; Wibe et al., 1990; Heitz,
1987). The possibility of a new primary tumour should
therefore be kept in mind if a patient with a prior history of
seminoma presents with high NSE levels, especially if the
elevated NSE is found many years after the initial treatment
of seminoma. In particular, NSE represents a tumour marker
both for lung cancer and malignant melanoma. Both malig-
nancies seem to occur at an increased risk in patients cured
for testicular cancer (FossA et al., 1990).
In conclusion, our pilot study confirms Kuzmits et al.'s
results: NSE seems to be a tumour marker in seminoma with
similar accuracy as HCG. NSE should be determined in cases
where tumour activity is suspected. As is the case with HCG,
minimal tumour burden is often not correlated with elevated
NSE values, and not all advanced cases have raised NSE
levels. In 30-50% of the patients with active disease raised
NSE levels, nevertheless, reflect the presence of malignant
tumour tissue. A normal level does, of course, not preclude
active disease. NSE may also be worthwhile as a tumour
marker during treatment of individual patients with
seminoma. The prognostic significance of serum NSE in
seminoma has to be defined in future studies.
References
CARNEY, D.N., IHDE, D.C., COHEN, M.H., MARANGOS, P.J., BUNN,
P.A.Jr. & MINNA, J.D. (1982). Serum neuron-specific enolase: a
marker for disease extent and response to therapy of small-cell
lung cancer. Lancet, i, 583.
FOSSA, A. & FOSSA, S.D. (1989). Serum LDH and HCG in semin-
oma. Br. J. Urol., 63, 408.
FOSSA, S.D., AASS, N. & KAALHUS, 0. (1988). Testicular cancer in
young Norwegians. J. Surg. Oncol., 39, 43.
FOSSA, S.D., LANGMARK, F., AASS, N., ANDERSEN, A.A., LOTHE, R.
& B0RRESEN, A.L. (1990). Second non-germ cell malignancies
after radiotherapy of testicular cancer with or without chemo-
therapy. Br. J. Cancer, 61, 639.
HEITZ, P.U. (1987). Neuroendocrine tumour markers. Curr. Top.
Pathol., 77, 279-306.
KUZMITS, R., SCHERNTHANER, G. & KRISCH, K. (1987). Serum
neuron-specific enolase. A marker for response to therapy in
seminoma. Cancer, 60, 1017.
NIEHANS, G.A., MANIVEL, J.C., COPLAND, G.T., SCHEITHAUER,
B.W. & WICK, M.R. (1988). Immunohistochemistry of germ cell
and trophoblastic neoplasms. Cancer, 62, 1113.
NIELSEN, O.S., MUNRO, A.J., DUNCAN, W. & 5 others (1990). Is
placental alkaline phosphatase (PLAP) a useful marker for
seminoma? Eur. J. Cancer, 26, 1049.
PAUS, E., FOSSA, A., FOSSA, S.D. & NUSTAD, K. (1988). High fre-
quency of incomplete human chorionic gonadotropin in patients
with testicular seminoma. J. Urol., 139, 542.
PAUS, E. & NUSTAD, K. (1989). Immunoradiometric assay for ax-
and tT-enolase (neuron-specific enolase), with use of monoclonal
antibodies and magnetizable polymer particles. Clin. Chem./, 35,
2034.
PECKHAM, M.J., MCELWAIN, T.J., BARRETT, A. & HENDRY, W.F.
(1979). Combined management of the malignant teratoma of the
testis. Lancet, ii, 267.
TAKASHI, M., HAIMOTO, H., KOSHIKAWA, T. & KATO, K. (1990).
Enolase isozymes in seminoma. Urol. Res., 18, 175.
WIBE, E., PAUS, E. & AAMDAL, S. (1990). Neuron specific enolase
(NSE) in serum of patients with malignant melanoma. Cancer
Lett., 52, 29.